시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 소림프구성 림프종 시장 보고서(2025년)
Small Lymphocytic Lymphoma Global Market Report 2025
상품코드 : 1717309
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,226,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,000,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,773,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

소림프구성 림프종 시장 규모는 향후 수년간 안정적인 성장세를 보일 것으로 예상되며, 2029년에는 연평균 4.45%의 연평균 복합 성장률(CAGR)로 38억 8,000만 달러에 달할 것으로 예측됩니다. 예측 기간 중 예상되는 성장의 원동력은 면역 요법에 대한 관심 증가, 표적 치료의 발전, 정밀 의학의 확대, 암 연구에 대한 투자 증가, 임상시험 증가입니다. 이 기간 중 예상되는 주요 동향으로는 표적치료와 면역치료의 혁신, 병용요법의 개발, 디지털 헬스 솔루션의 채택, 지지요법의 발전 등이 있습니다.

맞춤형 의료의 확대는 소림프구성 림프종 시장의 성장을 크게 촉진할 것으로 예측됩니다. 맞춤의료는 개인의 유전적, 환경적, 생활습관적 요인에 따라 치료 및 건강관리 결정을 조정하는 데 초점을 맞추었습니다. 유전체학, 생명공학, 데이터 분석의 발전으로 인해 보다 정확하고 효과적인 치료가 가능해지면서 발전이 가속화되고 있습니다. 소림프구성 림프종(SLL)은 표적 치료 및 맞춤 치료 전략을 지원하는 특정 유전자 돌연변이 및 바이오마커를 밝혀냄으로써 이 분야에서 매우 중요한 역할을 하고 있습니다. 예를 들어 Personalized Medicine Coalition의 보고에 따르면 2023년 FDA는 희귀질환에 대한 16건의 새로운 개인맞춤형 치료제를 승인했는데, 이는 2022년의 6건에서 크게 증가한 수치입니다. 이에 따라 개인맞춤형 의료의 발전이 소림프구성 림프종 시장의 성장을 가속할 것으로 예측됩니다.

소림프구성 림프종 시장의 주요 기업은 비공유결합형 BTK 억제제와 같은 혁신적인 치료법을 개발하여 치료 효과를 높이고, 기존 치료제에 대한 내성에 대응하며, 환자 예후를 개선하기 위해 노력하고 있습니다. 이들 억제제는 브루톤형 티로신 키나아제(BTK) 효소에 가역적으로 결합하여 작용하며, 공유결합 억제제에 따른 내성 및 부작용을 최소화하면서 B세포 악성 종양을 효과적으로 표적으로 삼고 있습니다. 예를 들어 2023년 12월 일라이 릴리는 BTK 억제제와 BCL-2 억제제를 포함한 최소 두 가지 이상의 이전 치료 경험이 있는 만성 림프구성 백혈병 또는 소림프구성 림프종 성인 환자에 대한 제이필카(성분명: 피르투르티닙)의 FDA 승인을 발표했습니다. 이번 승인은 이전 치료 경험이 많은 환자군의 중요한 니즈에 대응하는 것으로, 편의성과 강력한 치료 효과를 겸비한 경구용 치료 옵션을 제공한다는 점에서 의미가 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Small lymphocytic lymphoma (SLL) is a type of cancer that affects lymphocytes, a subset of white blood cells, and typically manifests in the lymph nodes. The goal of SLL treatment is to control the proliferation of abnormal lymphocytes, manage symptoms, and enhance the patient's quality of life through therapies such as chemotherapy, immunotherapy, or targeted treatments.

The primary product types for managing SLL include capsules, tablets, injections, and others. Capsules, which are solid dosage forms enclosed in a gelatin shell, are commonly used for the oral administration of targeted therapies and chemotherapy agents to treat SLL. Treatments are delivered through various routes, including oral and parenteral methods, among others. Available treatment options include chemotherapy, targeted therapy, stem cell transplants, monoclonal antibody therapy, and other approaches. These products are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. The key end users include hospitals, specialty clinics, homecare settings, and other healthcare providers.

The small lymphocytic lymphoma market research report is one of a series of new reports from The Business Research Company that provides small lymphocytic lymphoma market statistics, including the small lymphocytic lymphoma industry global market size, regional shares, competitors with the small lymphocytic lymphoma market share, detailed small lymphocytic lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the small lymphocytic lymphoma industry. This small lymphocytic lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The small lymphocytic lymphoma market size has grown steadily in recent years. It will grow from $3.12 billion in 2024 to $3.26 billion in 2025 at a compound annual growth rate (CAGR) of 4.71%. The growth during the historical period can be attributed to factors such as increased awareness and early detection, regulatory approvals, the expansion of clinical trials, greater understanding of small lymphocytic lymphoma (SLL), and higher participation in clinical trials.

The small lymphocytic lymphoma market size is expected to see steady growth in the next few years. It will grow to $3.88 billion in 2029 at a compound annual growth rate (CAGR) of 4.45%. The anticipated growth during the forecast period is driven by a heightened focus on immunotherapies, advancements in targeted therapies, the expansion of precision medicine, increased investment in cancer research, and a rise in clinical trials. Key trends expected in this period include innovations in targeted therapies and immunotherapies, the development of combination therapies, the adoption of digital health solutions, and progress in supportive care therapies.

The expansion of personalized medicine is anticipated to significantly boost the growth of the small lymphocytic lymphoma market. Personalized medicine focuses on tailoring treatments and healthcare decisions based on individual genetic, environmental, and lifestyle factors. Its development is fueled by advancements in genomics, biotechnology, and data analytics, enabling more precise and effective treatments. Small lymphocytic lymphoma (SLL) plays a pivotal role in this field by revealing specific genetic mutations and biomarkers that support targeted therapies and individualized treatment strategies. For example, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a considerable increase from six approvals in 2022. Consequently, the progress in personalized medicine is expected to drive the growth of the small lymphocytic lymphoma market.

Leading companies in the small lymphocytic lymphoma market are creating innovative treatments, such as non-covalent BTK inhibitors, to improve therapy effectiveness, address resistance to existing treatments, and enhance patient outcomes. These inhibitors work by reversibly binding to the Bruton's tyrosine kinase (BTK) enzyme, effectively targeting B-cell malignancies while minimizing resistance and side effects associated with covalent inhibitors. For instance, in December 2023, Eli Lilly and Company announced FDA approval for Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have undergone at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. This approval addresses a critical need in heavily pre-treated populations and provides an oral treatment option that combines convenience with strong therapeutic action.

In February 2024, Johnson & Johnson partnered with Pharmacyclics LLC to improve the delivery of IMBRUVICA, a BTK inhibitor used in treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other cancers. Pharmacyclics LLC specializes in providing services and products for SLL treatment. This collaboration aims to optimize IMBRUVICA's application, supporting better outcomes for patients with these conditions.

Major players in the small lymphocytic lymphoma market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals, Incyte Corporation, Exelixis Inc., Moffitt Cancer Center, Kite Pharma Inc., Spectrum Pharmaceuticals Inc., Aptose Biosciences Inc., Secura Bio Inc., Infinity Pharmaceuticals Inc., TG Therapeutics Inc.

North America was the largest region in the small lymphocytic lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small lymphocytic lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the small lymphocytic lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small lymphocytic lymphoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Lymphocytic Lymphoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small lymphocytic lymphoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for small lymphocytic lymphoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The small lymphocytic lymphoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Small Lymphocytic Lymphoma Market Characteristics

3. Small Lymphocytic Lymphoma Market Trends And Strategies

4. Small Lymphocytic Lymphoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Small Lymphocytic Lymphoma Growth Analysis And Strategic Analysis Framework

6. Small Lymphocytic Lymphoma Market Segmentation

7. Small Lymphocytic Lymphoma Market Regional And Country Analysis

8. Asia-Pacific Small Lymphocytic Lymphoma Market

9. China Small Lymphocytic Lymphoma Market

10. India Small Lymphocytic Lymphoma Market

11. Japan Small Lymphocytic Lymphoma Market

12. Australia Small Lymphocytic Lymphoma Market

13. Indonesia Small Lymphocytic Lymphoma Market

14. South Korea Small Lymphocytic Lymphoma Market

15. Western Europe Small Lymphocytic Lymphoma Market

16. UK Small Lymphocytic Lymphoma Market

17. Germany Small Lymphocytic Lymphoma Market

18. France Small Lymphocytic Lymphoma Market

19. Italy Small Lymphocytic Lymphoma Market

20. Spain Small Lymphocytic Lymphoma Market

21. Eastern Europe Small Lymphocytic Lymphoma Market

22. Russia Small Lymphocytic Lymphoma Market

23. North America Small Lymphocytic Lymphoma Market

24. USA Small Lymphocytic Lymphoma Market

25. Canada Small Lymphocytic Lymphoma Market

26. South America Small Lymphocytic Lymphoma Market

27. Brazil Small Lymphocytic Lymphoma Market

28. Middle East Small Lymphocytic Lymphoma Market

29. Africa Small Lymphocytic Lymphoma Market

30. Small Lymphocytic Lymphoma Market Competitive Landscape And Company Profiles

31. Small Lymphocytic Lymphoma Market Other Major And Innovative Companies

32. Global Small Lymphocytic Lymphoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Lymphocytic Lymphoma Market

34. Recent Developments In The Small Lymphocytic Lymphoma Market

35. Small Lymphocytic Lymphoma Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기